ENG/中
老虎證券
行情
交易
收費
下載
優惠與活動
幫助
TigerAI
學堂
機構
財富及資產管理人
自營交易機構
介紹經紀商
三方服務商
股權激勵
關於
關於我們
媒體報道
登入
立即註冊
Toggle
美股
詳情
本頁面由Tiger Trade Technology Pte. Ltd.提供服務
Aevi Genomic Medicine Inc
0.1659
0.0000
成交量:
- -
成交額:
- -
市值:
1,289.27萬
市盈率:
-0.56
高:
0.1659
開:
0.1659
低:
0.1659
收:
0.1659
52周最高:
0.3470
52周最低:
0.1100
股本:
7,771.38萬
流通股本:
6,789.62萬
量比:
- -
換手率:
- -
股息:
- -
股息率:
- -
每股收益(TTM):
-0.2957
每股收益(LYR):
-0.5014
淨資產收益率:
-372.06%
總資產收益率:
-104.54%
市淨率:
38.83
市盈率(LYR):
-0.33
資料載入中...
總覽
公司
新聞資訊
公告
公司資料
公司名字:
Aevi Genomic Medicine Inc
交易所:
NASDAQ
成立時間:
- -
員工人數:
- -
公司地址:
- -
官網:
http://www.medgenics.com
郵編:
- -
電話:
- -
傳真:
- -
簡介:
Medgenics, Inc.於2000年1月27日在特拉華州成立,其全資附屬公司 Medgenics Medical(以色列)Limited在以色列國依法成立。該公司從事於醫療技術和治療,開發專有創新技術平台,為一千多億美元的蛋白質療法市場提供新的療法。其BiopumpTM平台技術將患者的真皮組織轉成可形成蛋白質的“生物泵”,以在患者體內持續生產治療性蛋白質。當植入患者的皮下組織時,可以提供數月的蛋白療法,而不需要一系列頻繁注射。其Biopump平台技術已被驗證可以使用EPODURETM為貧血治療提供促紅細胞生成素(EPO),且貧血患者的血紅蛋白显示出高水平和穩定性,而這些患者大都是在I/II期用藥達6個月及以上的慢性腎臟病(CKD)患者,且試驗結果显示其中一個病人在長達36月內穩定在高血紅蛋白水平。其Biopump是組織微泵(MO),形成於患者的牙籤大小的皮膚組織,可以產生並分泌特定的蛋白質。該公司已經開發出名為DermaVac的專有設備,以方便微泵的去除和Biopumps的植入。
{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投,即時串流報價與多種工具,立即開戶享更多優惠!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/GNMX/company"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"GNMX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","market":"US","secType":"STK","nameCN":"Aevi Genomic Medicine Inc","latestPrice":0.1659,"timestamp":1580763600000,"preClose":0.1659,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":67896168,"shares":77713782,"eps":-0.295664,"marketStatus":"退市","change":0,"latestTime":"02-03 16:00:00 EST","open":0.1659,"high":0.1659,"low":0.1659,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.295664,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1774857600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1302235200000,"exchange":"NASDAQ","adjPreClose":0.1659,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"GNMX\",,,,,undefined,":{"symbol":"GNMX","floatShares":67896168,"roa":"-104.54%","roe":"-372.06%","lyrEps":-0.501371,"shares":77713782,"dividePrice":0,"high":0.1659,"amplitude":0,"preClose":0.1659,"low":0.1659,"week52Low":0.11,"pbRate":"38.83","week52High":0.347,"institutionHeld":0,"latestPrice":0.1659,"eps":-0.295664,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.295664,"open":0.1659},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/GNMX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2019-11-14","symbol":"GNMX","fiscalQuarterEnding":"2019/09","expectedEps":-0.05,"name":null,"time":"","type":"earning","dateTimestamp":1573707600000,"reportTimeType":"","actualEps":-0.06},{"market":"US","date":"2019-08-13","symbol":"GNMX","fiscalQuarterEnding":"2019/06","expectedEps":-0.1,"name":null,"time":"","type":"earning","dateTimestamp":1565668800000,"reportTimeType":"","actualEps":-0.06},{"market":"US","date":"2019-05-14","symbol":"GNMX","fiscalQuarterEnding":"2019/03","expectedEps":-0.1,"name":null,"time":"","type":"earning","dateTimestamp":1557806400000,"reportTimeType":"","actualEps":-0.07},{"market":"US","date":"2018-11-01","symbol":"GNMX","fiscalQuarterEnding":"2018/09","expectedEps":-0.16,"name":null,"time":"","type":"earning","dateTimestamp":1541044800000,"reportTimeType":"","actualEps":-0.12},{"market":"US","date":"2018-08-02","symbol":"GNMX","fiscalQuarterEnding":"2018/06","expectedEps":-0.15,"name":null,"time":"","type":"earning","dateTimestamp":1533182400000,"reportTimeType":"","actualEps":-0.14}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"GNMX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"GNMX\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.medgenics.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":-0.0223},{"period":"1month","weight":-0.0852},{"period":"3month","weight":-0.0814},{"period":"6month","weight":-0.0419},{"period":"1year","weight":0.1182},{"period":"ytd","weight":-0.0701}],"compareStock":{"symbol":"SPY","name":"標普500ETF"},"description":"Medgenics, Inc.於2000年1月27日在特拉華州成立,其全資附屬公司 Medgenics Medical(以色列)Limited在以色列國依法成立。該公司從事於醫療技術和治療,開發專有創新技術平台,為一千多億美元的蛋白質療法市場提供新的療法。其BiopumpTM平台技術將患者的真皮組織轉成可形成蛋白質的“生物泵”,以在患者體內持續生產治療性蛋白質。當植入患者的皮下組織時,可以提供數月的蛋白療法,而不需要一系列頻繁注射。其Biopump平台技術已被驗證可以使用EPODURETM為貧血治療提供促紅細胞生成素(EPO),且貧血患者的血紅蛋白显示出高水平和穩定性,而這些患者大都是在I/II期用藥達6個月及以上的慢性腎臟病(CKD)患者,且試驗結果显示其中一個病人在長達36月內穩定在高血紅蛋白水平。其Biopump是組織微泵(MO),形成於患者的牙籤大小的皮膚組織,可以產生並分泌特定的蛋白質。該公司已經開發出名為DermaVac的專有設備,以方便微泵的去除和Biopumps的植入。","exchange":"NASDAQ","name":"Aevi Genomic Medicine Inc","nameEN":"Aevi Genomic Medicine Inc"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"GNMX\",market:\"US\",,,undefined,":null}}